Mereo BioPharma Group plc Notice of General Meeting (0137Y)
04 9월 2020 - 3:00PM
UK Regulatory
TIDMMPH
RNS Number : 0137Y
Mereo BioPharma Group plc
04 September 2020
Mereo BioPharma Group plc
Notice of General Meeting
London and Redwood City, Calif., September 4, 2020 - Mereo
BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the
Company", a clinical-stage biopharmaceutical company focused on
oncology and rare diseases, today announces a General Meeting of
the Company to be held at 11:00 a.m. on 28 September 2020 at 1
Cavendish Place, London W1G 0QF, United Kingdom.
A copy of the Notice of General Meeting is available on the
Company's website: https://www.mereobiopharma.com/gm-20-09 and the
Notice of General Meeting or, as appropriate, a notification of its
availability online, will be posted to shareholders shortly.
Under the Companies Act 2006, the directors of a public company
are required to lay its annual accounts and reports before the
company in general meeting by not later than the end of the period
for the filing of those accounts and reports with the Registrar of
Companies. The period for filing the annual accounts and reports is
ordinarily six months from the accounting reference date. However,
earlier this year the Company was granted a three-month extension
of this period by Companies House to 30 September 2020 in respect
of its annual report and accounts for the financial year ended 31
December 2019 (the "Annual Accounts").
The Company's annual general meeting (the "AGM") was held on 29
June 2020. The Annual Accounts were published by the Company on 16
June 2020 but not in time for them to be laid before the AGM.
Accordingly, the Directors are now convening the General Meeting at
which the Annual Accounts will received by the shareholders.
Attendance at the General Meeting
On 23 March 2020, the UK Government published compulsory
measures on staying at home and away from others (social
distancing) to address the spread of COVID-19. The measures became
law in England on 26 March 2020. The Company and its shareholders
are required to comply with these measures in the holding of the
General Meeting. To assist companies and shareholders to comply
with the measures, the UK Government has temporarily allowed
companies to suspend shareholders' ability to attend meetings in
person. In light of these measures, it is expected that the General
Meeting will be held as a closed meeting and shareholders will not
be allowed to attend the General Meeting in person. Accordingly,
all shareholders are encouraged to appoint the Chairman of the
General Meeting as proxy to vote on the proposed resolutions. If
the COVID-19 measures are continuing at the time of the General
Meeting, any shareholder seeking to attend the General Meeting in
person will be refused entry.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for oncology and rare diseases. Mereo's
lead oncology product candidate, etigilimab ("Anti-TIGIT"), has
completed a Phase 1a dose escalation clinical trial in patients
with advanced solid tumors and has been evaluated in a Phase 1b
study in combination with nivolumab in select tumor types. Mereo's
rare disease product portfolio consists of setrusumab, which has
completed a Phase 2b dose-ranging study in adults with osteogenesis
imperfecta ("OI"), as well as alvelestat, which is being
investigated in a Phase 2 proof-of-concept clinical trial in
patients with alpha-1 antitrypsin deficiency ("AATD").
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
N+1 Singer (Nominated Adviser and Broker
to Mereo ) +44 (0)20 7496 3081
Phil Davies
Will Goode
Aubrey Powell
Burns McClellan (US Investor Relations Adviser
to Mereo) +1 212 213 0006
Lisa Burns
Steve Klass
FTI Consulting (UK Public Relations Adviser
to Mereo ) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@mereobiopharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOGFIFIIAAISIII
(END) Dow Jones Newswires
September 04, 2020 02:00 ET (06:00 GMT)
Mereo Biopharma (LSE:MPH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Mereo Biopharma (LSE:MPH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
